Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hemophilia B: full-pipeline trial registry
9 of 21 indexed Hemophilia B trials are currently recruiting.
Corpus placement: #797 of 28,707 conditions by registered trial count.
21 US clinical trials · 9 currently recruiting · #797 of 28,707 conditions by registered trial count
Hemophilia B: 21 US clinical trials tracked, 9 recruiting.
Hemophilia B is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 5 of these trials.
Enrollment posture brief
Registry condition hemophilia-b
OPEN 9 | RECR 43% | LATE 7 | EARLY 6 | RANK #797 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Acute Myelogenous Leukemia (AML) (43% recruiting · 7 trials)
Hemophilia B lists 9 open slots (43% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hemophilia B on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hemophilia B is recruiting above its size-band peers.
9 of 21 indexed trials (42.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hemophilia B research.
Pfizer accounts for 5 of 21 trials (23.8%). 13 distinct sponsors appear on at least one study for this condition label.
-
Most Hemophilia B trials plan to enrol fewer than 100 people.
Median target enrolment is 35 among the 21 trials that report a genuine target (sentinel values excluded). 13 of those (61.9%) plan for fewer than 100 participants.
-
Hemophilia B splits between interventional and observational designs.
14 interventional and 7 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
21 total, page 1 of 1
An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B
CSL Behring
NCT06008938
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Pfizer
NCT05145127
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Pfizer
NCT05568719
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
Regeneron Pharmaceuticals
NCT06379789
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Pfizer
NCT05611801
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
CSL Behring
NCT06003387
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
Equilibra Bioscience
NCT06349473
BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
Be Biopharma
NCT06611436
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
CSL Behring
NCT07080905
A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B
Pfizer
NCT03861273
Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B
Baxalta now part of Shire
NCT01687608
Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B
Pfizer
NCT03307980
Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B
St. Jude Children's Research Hospital
NCT00979238
Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
Sangamo Therapeutics
NCT04628871
A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
Regeneron Pharmaceuticals
NCT05568459
Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study
Weill Medical College of Cornell University
NCT00936312
Needs Assessment of Knowledge, Beliefs, and Attitudes of Patients With Hemophilia B About Gene Therapy
St. Jude Children's Research Hospital
NCT05044845
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors
Genzyme, a Sanofi Company
NCT03417245
AAV Gene Therapy Screening/Observational Protocol (ECLIPSE)
Spur Therapeutics
NCT04272554
Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia
Virginia Commonwealth University
NCT01090206
Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B
Ultragenyx Pharmaceutical
NCT02971969
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
| Phase 3 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Hemophilia B records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hemophilia B trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hemophilia B page
21 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Hemophilia B trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pfizer sponsors the most Hemophilia B trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hemophilia B condition card totals 21 registered trials; most-linked intervention Vitamin D and calcium; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.